← Back to Search

Anticoagulant

Ticagrelor first for Heart Attack (DEFINE CCS Trial)

Phase 4
Recruiting
Research Sponsored by Nova Scotia Health Authority
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 7 days
Awards & highlights

DEFINE CCS Trial Summary

This trial will compare two drug treatments in heart attack survivors to see which one has fewer risks of bleeding/clotting. Both treatments are already approved for heart attack patients.

Eligible Conditions
  • Heart Attack
  • Blood Clot

DEFINE CCS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~7 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 7 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Bleeding time
Secondary outcome measures
Differential effects on fibrin clot lysis time
Differential effects on inflammatory markers (white cell count and CRP)

DEFINE CCS Trial Design

2Treatment groups
Active Control
Group I: Ticagrelor firstActive Control2 Interventions
Patients will be treated with ticagrelor 60 mg twice a day for one week then on Day 21, will be treated with rivaroxaban 2.5 mg twice a day for one week.
Group II: Rivaroxaban firstActive Control2 Interventions
Patients will be treated with rivaroxaban 2.5 mg twice a day for one week then on Day 21, will be treated with ticagrelor 60 mg twice a day for one week.

Find a Location

Who is running the clinical trial?

Nova Scotia Health AuthorityLead Sponsor
263 Previous Clinical Trials
84,916 Total Patients Enrolled
~8 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top